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ABSTRACT 
Helicobacter pylori is a prevalent cause of gastrointestinal infections. Recently, several studies have shown 
a relationship between H. pylori infection and a variety of extradigestive manifestations. The aim of this 
study was to review the literature regarding the prevalence of this infection in cases of central serous 
chorioretinopathy (CSR). We reviewed the EMBASE, Cochrane Library, and Google Scholar search engines; 
hand-searched many journals; and searched the cited references in published articles for relevant studies. 
We assessed 81 studies for eligibility. Finally, nine articles that met the inclusion criteria were included. The 
relationship between H. pylori infection (as the etiologic factor) and chorioretinal involvement was 
assessed by the effect size with 95% confidence interval (CI). Both fixed- and random-effects models 
showed that the prevalence of H. pylori infection in patients with CSR was significantly higher than in the 
control group (2.5-fold and 2.7-fold higher, respectively; P < 0.01). The results were not significantly 
different between the two models. Treatment of H. pylori infection should be considered in patients with 
CSR. However, additional randomized controlled clinical trials are required to determine the possible role 
of H. pylori eradication in the prognosis and treatment of patients with CSR. 
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INTRODUCTION
Helicobacter pylori is a helix-shaped, Gram-negative 
microphilic bacterium that inhabits various regions of the 
stomach and duodenum. It is one of the most common 
causes of gastric infections worldwide [1] and the 
etiological basis of many diseases such as gastritis, gastric 
ulcer, gastric cancer, and lymphoma. Notably, H. pylori is 
suspected as a possible cause of early-onset focal 
obstructive arterial diseases [2]. In the past decade, 
several studies have investigated the possible 
relationship between H. pylori infection and various 
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other complications and manifestations, such as 
Raynaud’s phenomenon, cardiovascular diseases, 
pulmonary diseases, urticaria, and rosacea [3, 4]. 
Recently, the relationship between H. pylori infection and 
eye diseases, including blepharitis, uveitis, dry eye 
syndrome, glaucoma, and central serous 
chorioretinopathy (CSR), has been a matter of interest 
[5]. However, it is unclear how H. pylori might affect the 
eye [5, 6]. CSR is an idiopathic condition that is 
characterized by the development of a well-
circumscribed serous detachment of the neurosensory 
retina (neuroepithelium), resulting from altered barrier 
and deficient pumping function at the level of the retinal 
pigment epithelium (RPE) in the macular region [7]. 
Studies have estimated the annual incidence rate of CSR, 
which is 10/100,000 in men (six times more common 
than in women) [8]. Many individuals with CSR may be 
asymptomatic or may suffer from visual disturbances, 
such as a sudden-onset decrease of vision (blurred 
vision), color vision deficiency, micropsia, 
metamorphopsia, or central scotoma [8]. 
A decrease in visual acuity (VA) can be detected with a 
Snellen visual acuity chart; color vision changes can be 
measured via standard testing (for example, using 
pseudoisochromatic plates such as the Ishihara plate, or 
by panel tests, such as the Lanthony 15-Hue Desaturated 
Test); central scotoma may be identified on macular 
perimetry (microperimetry) or by using the Amsler grid 
test [9]. Retinal lesions can be observed on optical 
coherence tomography (OCT) images. Occasionally, 
angiographic studies (fluorescein angiography, 
indocyanine green angiography, or three-dimensional 
angiography) are required for further investigation [10]. 
Fortunately, CSR exhibits a benign natural course and 
symptoms improve over a period of 3–4 months [11]. 
Because of the spontaneous resolution of the 
neurosensory retinal detachment (RD), the prognosis of 
patients with CSR is often favorable; however, a small 
percentage of patients can progress to chronic or 
progressive disease with severe visual loss for more than 
6 months; this is defined as diffuse decompensation of 
the RPE [11]. Men become more susceptible in the third 
to fifth decades of life, and are more likely to be affected 
if they exhibit a Type A personality. Other known 
predisposing factors include corticosteroid therapy or 
psychotropic medications, emotional strain, organ 
transplant, pregnancy, and connective tissue diseases, 
such as systemic lupus erythematosus [8]. 
The pathophysiology of CSR remains unknown, and no 
effective treatment is available. Recently, immune-
dependent mechanisms have been proposed. A possible 
immune mechanism is based on the molecular mimicry 
between H. pylori-expressed antigens and homologous 
host proteins (e.g., vascular endothelial proteins) [12]. 
Many other studies have investigated the causal 
relationship between H. pylori infection and CSR [2, 13-
15]. In a prospective pilot study of 16 patients with CSR 
and diffuse retinal pigment epitheliopathy (DRE), the 
prevalence of H. pylori infection was significantly higher 
in patients with CSR than in the general population [2]. In 
another study, the prevalence was also significantly 
higher in patients with CSR than in a control population 
from the same country [16]. Subsequent investigations 
confirmed that H. pylori is an important etiologic factor in 
CSR [12-21]. Nevertheless, the prevalence of H. pylori 
infection in patients with CSR remains controversial, as 
some studies have reported that the prevalence of this 
infection is not higher in patients with CSR than in 
controls [22, 23]. The aim of this study was to 
systematically review the literature regarding the 
prevalence of H. pylori infection in CSR to more clearly 
describe the relationship between H. pylori infection and 
chorioretinal involvement in CSR. All retrospective 
studies that investigated H. pylori infection as an 
etiologic factor in CSR were analyzed. 
MATERIALS AND METHODS 
This review study was conducted in accordance with the 
guidelines for systematic reviews in health care [24]. An 
extensive article search was conducted using the 
MEDLINE, EMBASE, and Cochrane Library databases, with 
a search period through March 2016 and no language 
restriction. Retrospective observational studies regarding 
the prevalence of H. pylori infection in patients with CSR 
were screened using a search strategy that was based on 
the following Medical Subject Heading (MeSH) terms:  
“(((central serous Chorioretinopath*) OR 
(Chorioretinopath* AND central serous) OR (serous 
Chorioretinopath* AND central) OR (central serous 
Retinopath*) OR (Retinopath* AND central serous) OR 
(serous Retinopath* AND central) OR cscr OR CSR OR 
CSC)) AND (((campylobacter pylori) OR (rdxa protein AND 
h. pylori) OR (LPS AND h. pylori) OR (helicobacter pylori 
lipopolysaccharide) OR (antibacterial cecropin-like h. 
pylori peptide hp (2-20)) OR (vacuolating cytotoxin AND 
h. pylori) OR (hvlt protein AND helicobacter pylori) OR 
(vacuolating toxin AND helicobacter pylori) OR 
(helicobacter pylori vacuolating toxin) OR (hydrogenase 
nickel incorporation protein hypa AND h pylori) OR (hypa 
protein AND helicobacter pylori) OR (outer membrane 
protein homb AND h pylori) OR (tumor necrosis factor-
alpha-inducing protein AND helicobacter pylori) OR 
(hp0596 protein AND h pylori) OR (tnf-alpha-inducing 
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protein AND helicobacter pylori) OR (clone p32 protein 
AND h pylori) OR (asd enzyme AND h pylori) OR (ylxh 
protein AND h pylori)))”. 
The search strategy for the MEDLINE, EMBASE, and 
Cochrane Library databases was similar to that utilized 
for the PubMed database. In the next step, we 
performed a comprehensive literature search using the 
Google Scholar search engine (scholar.google.com). 
Additionally, a manual search was conducted in the 
following journals: American Journal of Ophthalmology 
(www.ajo.com), Retina Journal 
(www.journals.lww.com/retinajournal), British Journal of 
Ophthalmology (bjo.bmj.com), and European Journal of 
Ophthalmology (www.eur-j-ophthalmol.com).  
Finally, the cited references in the retrieved studies were 
manually reviewed for additional relevant results. After 
the structured search, we assessed 81 studies for 
eligibility, and their full-text versions were retrieved. All 
papers were reviewed by three independent 
investigators to avoid potential bias or errors. Essential 
data extracted by researchers, and literature with an 
agreement rate above 80%, were included. Discrepancies 
were resolved by discussion or referral to a fourth 
investigator if necessary (Fig 1).  
Of the included studies, two did not have a control group 
and two did not provide sufficient data for analysis. 
Therefore, the data of five studies were ultimately 
entered into Comprehensive Meta-Analysis (CMA.2) 
software for analysis. To assess the overall effect size, we 
used both fixed- and random-effects models (Fig 2). 
According to these models, the prevalence of H. pylori 
infection was 2.5-fold and 2.7-fold higher, respectively, in 
patients with CSR than in the control group (fixed-effects 
model: OR = 2.52, 95% CI 1.64–3.89; random-effects 
model: OR = 2.77, 95% CI 1.53–5.02) (Fig 2). 
 
 
Figure 1. This figure shows the methodology of the study, in a stepwise fashion. 
 
In this study, the final agreement rate among the 
reviewers was 90%. The following information was 
obtained from all studies and entered in an extraction 
table: the first author’s surname, the publication year, 
the city and country, the number of subjects, and the 
odds ratio (OR) with P-value (for studies that contained a 
control group). Data were analyzed by CMA.2 software. 
The relationship between H. pylori infection (as an 
etiologic factor) and chorioretinal involvement was 
assessed by the effect size with 95% confidence interval 
(CI). To estimate the overall effect size, we used fixed- 
and random-effects models. In addition, by utilization of 
Literature 
Search  
•MEDLINE, PubMed, EMBASE, and Cochrane Library (n= 49) 
•Retina, AJO, BJO, Eur J Ophthalmol, Hand Search in Journals (n= 27) 
•Relevant Cited Study (n= 5) 
Study Selection 
& Assessment 
•Study Extracted by Independent Investigators  (n= 23) 
•Resolved Discrepancies by Fourth Investigator (n= 2) 
•Irrelevant Studies Excluded (n= 45) 
Inclusion & 
Exclusion 
Criteria  
•Duplicate Studies Excluded (n= 0) 
•Reviews Excluded (n= 6) 
•Comments and Letters Excluded (n= 0) 
Included 
Study 
•Study Included (n= 9) 
•Data collected 
Statistical 
Analysis 
•Illustration of Funnel Plot and Forest Plot 
•Overall Effect Size, Fixed-Effects Model and Random-Effects Model 
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a funnel plot, these two models were evaluated to 
identify any potential publication bias. 
RESULTS 
Of the 81 studies assessed for eligibility, a total of nine 
retrospective studies met the criteria for entry and were 
included in the analysis. The studies examining the 
prevalence of H. pylori infection in CSR included a total of 
309 patients with CSR and 295 cases in control groups, or 
in a historical control population (as in two studies). The 
extracted data are listed in Table 1. 
The prevalence of H. pylori infection was significantly 
greater in patients with CSR than in the control group (P 
< 0.01) and there was no difference between the two 
models (Table 2). 
Furthermore, funnel plot analysis revealed that there 
was no publication bias (Fig 3). 
 
Table 1. Extracted Data from All Included Studies 
Authors Year City, country Prevalence of H. pylori 
infection in patients with 
CSR 
Prevalence of H. pylori 
infection in the control group 
Odds ratio (P-
value) 
Roshani et al. [21] 2014 Tehran, Iran 30/35 (85.7%) 76/138 (55.1%) 4.895 (0.001) 
Warrow et al. [23] 2012 New York, USA 3/18 (16.7%) ---- ---- 
Misiuk-Hojlo et al. 
[13] 
2009 Wroclaw, Poland 37/55 (67.0%) 26/55 (47.0%) 2.29 (<0.05) 
Kmera-Muszynska et 
al. [18] 
2008 Warszawie, 
Poland 
11/14 (78.5%) ----- ---- 
Feghhi et al. [22] 2008 Ahvaz, Iran 37/54 (68.5%) 38/59 (65.0%) 1.20 (0.64) 
Asensio-Sanchez et 
al. [14] 
2008 Valladolid, Spain 11/16 (68.75%) 6/20 (30.0%) 5.13 (<0.05) 
Cotticelli et al. [15] 2006 Napoli, Italy 18/23 (78.2%) 10/23 (43.5%) 4.6 (<0.03) 
Ahnoux-Zabsonre et 
al. [16] 
2004 Côte d’Ivoire, 
France 
31/78 (39.7%) Overall population of 
58,419,710 inhabitants of 
France in 1999 (25.4%) 
---- 
Mauget-Faysse et al. 
[2] 
2002 Lyon, France 9/16 (56.3%) Historical control population 
(27.5%) 
---- 
H. pylori, Helicobacter pylori; CSR, central serous chorioretinopathy 
 
 
Figure 2. Prevalence of Helicobacter Pylori Infection in Central Serous Chorioretinopathy (CSR) Group versus Control Group based on 
Random-Effects Model (up) and Fixed-Effects Model (down). 
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Table 2. The Results of Systematic Review and Meta-analysis 
Model Number of Studies Point estimate Lower limit Upper limit P-value 
Fixed 5 2.528 1.643 3.890 < 0.001 
Random 5 2.778 1.535 5.027 0.001 
 
 
 
 
Figure 3. Funnel Plot of Standard Error against Log Odds Ratio. 
 
 
DISCUSSION
This review of the literature was conducted to elucidate 
the relationship between H. pylori infection and CSR. 
Data from 302 patients with CSR were included in this 
study. A total of nine papers were selected to study the 
possible relationship between H. pylori infection and CSR, 
and five papers were included in the final analysis. The 
results of fixed- and random-effects models showed that 
the prevalence of H. pylori infection in patients with CSR 
is 2.5 and 2.7 times higher, respectively, compared with 
the control group. Similarly, in a prospective pilot study 
of 16 patients with CSR and DRE, the prevalence of H. 
pylori infection was significantly higher in patients with 
CSR than in the general population [2]. In another study, 
the prevalence was also significantly higher in patients 
with CSR than in a control population from the same 
country [16]. These results have been confirmed by many 
other studies [2, 13-16, 18, 22]. For example, in a 
prospective study involving 35 CSR cases and 135 
controls, Roshani et al. (2014) demonstrated that the 
prevalence of H. pylori infection was significantly higher 
in patients with CSR than in controls. They reported that 
the symptoms of patients with CSR improved after 
successful H. pylori eradication using standard therapy, 
and suggested additional randomized controlled clinical 
trials were needed to confirm the usefulness of H. pylori 
eradication as a therapeutic option for patients with CSR 
who exhibit an H. pylori infection [21]. 
In contrast, a prospective study by Warrow et al. (2012) 
reported a much lower prevalence of H. pylori infection 
in patients with CSR, compared with previous, 
predominantly retrospective studies (prevalence range: 
44%–78%). This disparity may have arisen because H. 
pylori testing in the study by Warrow et al. was 
performed during periods of CSR quiescence in four of 
the negative subjects [23]. Ahnoux-Zabsonre et al. (2004) 
reported that recurrent CSR was always associated with 
the presence of H. pylori infection, whereas 
improvement in both symptoms (blurred vision and 
decreased visual acuity) and signs (fundoscopic findings) 
was associated with successful H. pylori eradication [16]. 
In a study by Mauget-Faysse et al. (2002), 16 patients 
with long-lasting CSR (> 6 months) or DRE were tested for 
gastric H. pylori infection. The authors reported that 
56.3% of patients were positive for H. pylori, which was 
significantly higher than the rate of the historical control 
population (27.5%) [2]. The same study also reported 
that the prevalence of H. pylori infection was significantly 
higher in patients with CSR and DRE (39.7%), compared 
with the general French population (25.4%) [16]. The 
authors indicated that these results could provide a basis 
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for further studies regarding the etiopathogenesis of 
chronic CSR or DRE, which could provide evidence to 
support effective therapy, i.e., H. pylori eradication [2]. 
Kmera-Muszinska et al. (2008) suggested a role for H. 
pylori infection in the etiopathogenesis of CSR, based on 
a survey of 14 patients with histopathologically 
confirmed H. pylori infection [18]. The association 
between H. pylori infection and atherosclerosis has been 
documented in previous studies of cagA-positive strains 
[25]. This study provided new clues regarding the 
pathophysiology of CSR and its relationship with H. pylori 
infection. It has been suggested that antibodies against 
the CagA antigen may cross-react with vascular 
endothelial antigens, thus promoting vascular wall 
damage and atherosclerosis development [25, 26]. 
Endothelial cell dysfunction via the proposed mechanism 
could explain the pathophysiology of CSR in H. pylori-
infected patients. However, further studies are needed 
to investigate this and other possible autoimmune 
mechanisms. One of the limitations of this study was the 
small number of included papers and the lack of a control 
group in two of these papers. In conclusion, this review 
confirmed that the prevalence of H. pylori infection is 
significantly higher in patients with CSR. Treatment of H. 
pylori infection should be considered in patients with 
CSR. However, this recommendation merits further 
investigation. Additional clinical trials are required to 
clearly discern the role of H. pylori eradication in the 
prognosis and treatment of patients with CSR. If this 
relationship is confirmed, a new therapeutic protocol for 
CSR could be introduced in the future. 
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